ArticlemBio2019

Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma.

Carolina Caro-Vegas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.